By Pratik Jain (Reuters) - The U.S. Food and Drug Administration's panel of outside experts did not lend its support to Cytokinetics Inc's heart drug,.
Patients with advanced chronic kidney disease who have hyper- or hypokalemia are at higher risk for ER visits and hospitalization, especially those with high potassium levels.